Opyt primeneniya dienogesta (2 mg) u patsientok s adenomiozom
- Authors: Korennaya V.V1
-
Affiliations:
- Issue: No 3 (2015)
- Pages: 22-24
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287713
- ID: 287713
Cite item
Open Access
Access granted
Abstract
Adenomyosis is one of the most serious diseases of the female genital sphere. The most typical symptoms include menorrhagia, pelvic pain and dysmenorrhea. Quite often, adenomyosis and leyomatoz are combined with each other, making it difficult to differentiate these conditions. Despite the fact that adenomyosis is known about more than a century, epidemiological studies are extremely limited. Minimally invasive procedures for the treatment of adenomyosis have limited effectiveness. The objectives of this review included evaluation of the available epidemiological data, risk factors and clinical phenotypes in order to assess existing experience of surgical and medical treatments of adenomyosis to date.
Keywords
Full Text
References
- Benagiano G., Brosens I. History of adenomyosis. Best Pract. Res. Clin. Obstet. Gynaecol. 2006;20:449-63.
- Renner S.P., Lermann J., Hackl J., et al. Chronische Erkrankung. Endometriose Geburtsh Frauenheilk. 2012;72:914-19.
- Garcia L., Isaacson K. Adenomyosis: review of the literature. J. Minim Invasive Gynecol. 2011;18:428-37.
- Azziz R. Adenomyosis: current perspectives. Obstet. Gynecol. Clin. North Am. 1989; 16:221-35.
- Vercellini P., Parazzini F., Oldani S., Panazza S., Bramante T., Crosignani P.G. Adenomyosis at hysterectomy: a study on frequency distribution and patient characteristics. Hum. Reprod. 1995;10:1160-62.
- Parazzini F.V.P., Panazza S., Chatenoud L., Oldani S., Crosignani P.G. Risk factors for adenomyosis. Hum. Reprod.1997;12:1275-79.
- Bergholt T., Eriksen L., Berendt N., Jacobsen M., Hertz J.B. Prevalence and risk factors of adenomyosis at hysterectomy. Hum. Reprod. 2001;16:2418-21.
- Vercellini P., Vigano P., Somigliana E., Daguati R., Abbiati A., Fedele L. Adenomyosis: epidemiological factors. Best Pract. Res. Clin. Obstet. Gynaecol. 2006;20:465-77.
- Parazzini F., Mais V., Cipriani S., Busacca M., Venturini P. Determinants of adenomyo sis in women who underwent hysterectomy for benign gynecological conditions: results from a prospective multicentric study in Italy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 143:103-06.
- Rabinovici J., Stewart E.A. New interventional techniques for adenomyosis. Best Pract. Res. Clin. Obstet. Gynaecol. 2006;20:617-36.
- Bruner-Tran K., Herington J., Duleba A., Taylor H. Medical Management of Endometriosis: Emerging Evidence Linking Inflammation to Disease Pathophysiology Osteen Minerva Ginecol. 2013;65(2):199-213.
- Sallam H.N., Garcia-Velasco J.A., Dias S., Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis (Review). Cochrane Collaboration. Published by John Wiley & Sons, Ltd, 2002.
- Romanek K., Bartuzi A., Bogusiewicz M., Rechberger T. Risk factors for adenomyosis in patients with symptomatic uterine leiomyomas. Clin. Pol. 2010:81:678-80.
- Серова И.Ф. Современные возможности медикаментозной терапии миомы матки и эндометриоза. РМЖ. 2002;10(7):368-70.
- Sagsveen M., Farmer J.E., Prentice A., Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: Bone mineral density. Cochrane Database Syst. Rev. 2003;4:CD001297.
- Zito G., Luppi S., Giolo E., Martinelli M., Venturin I. Medical Treatments for Endometriosis-Associated Pelvic Pain. Biomed. Res. Int. 2014;2014:191967.
- Кузнецова И.В. Эндометриоз: патофизиология и выбор лечебной тактики. Гинекология. 2008;10(5):74-9.
- Razzi S., Luisi S., Ferretti C., Calonaci F., Gabbanini M., Mazzini M., Petraglia F. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007;135(2):188-90.
- Сотникова Л.С., Удут Е.Н., Насырова Р.Ф., Тонких О.С. Современная терапия эндометриоза. Опыт применения визанны. Проблемы репродукции. 2012;6:34-9.
- Sasa H., Imai K., Suzuki A., Sei K., Makimura N., Furuya K. Comparison of low-dose dienogest with low-dose danazol for long-term treatment of adenomyosis. Obstet. Gynecol. 2014;123(Suppl 1):97S-8S.
- Yamanaka A., Kimura F., Kishi Y., Takahashi K., Suginami H., Shimizu Y., Murakami T. Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 179:170-74.
Supplementary files
